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Méndez Romero et al. International Journal of Radiation Oncology  Biology  Physics2Methods and Materials: A shared web-based registry of patients with liver metastases treated with SBRT was developed by
13 centers (12 in the Netherlands and 1 in Belgium). All the centers had previously agreed on the items to be collected, the
fractionation schemes, and the organs-at-risk constraints to be applied. Follow-up was performed at the discretion of the cen-
ters. Patient, tumor, and treatment characteristics were entered in the registry. Only liver metastases treated individually as
independent targets and with at least 1 radiologic follow-up examination were considered for local control analysis. Toxicity
of grade 3 or greater was scored according to the Common Terminology Criteria of Adverse Events (v4.03).
Results: Between January 1, 2013, and July 31, 2019, a total of 515 patients were entered in the web-based registry. The
median age was 71 years. In total, 668 liver metastases were registered, and 447 were included for local control analysis.
The most common primary tumor origin was colorectal cancer (80.3%), followed by lung cancer (8.9%) and breast cancer
(4%). The most-used fractionation scheme was 3x18-20 Gy (36.0%), followed by 8x7.5 Gy (31.8%), 5x11-12 Gy (25.5%),
and 12x5 Gy (6.7%). The median follow-up time was 1.1 years for local control and 2.3 years for survival. Actuarial 1-year
local control was 87%; 1-year overall survival was 84%. Toxicity of grade 3 or greater was found in 3.9% of the patients.
Conclusions: This multi-institutional study confirms the high rates of local control and limited toxicity in a large patient
cohort. Stereotactic body radiation therapy should be considered a valuable part of the multidisciplinary approach to treating
liver metastases.  2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
A multidisciplinary approach is essential to guarantee the
most personalized treatment for patients with liver metas-
tases. Thus, if the best possible treatment or combination of
complementary options is to be provided, optimal collab-
oration is required.
In view of Hellman’s proposal that oligometastatic dis-
ease is a distinct cancer state between locally confined
cancer and systemically metastasized disease, patients with
limited metastatic disease may benefit from local directed
therapies.1 With local recurrence rates lower than 10% and
3-year overall survival rates of 72%, surgical resection is
considered the gold standard treatment for liver metastases
from colorectal cancer.2,3 In the meantime, percutaneous
thermal ablation has evolved as a complement to resection
and as a single treatment modality and is now regarded as a
potentially curative local treatment option.2,4,5 After radi-
ofrequency ablation (RFA) for colorectal liver metastases,
local tumor-recurrence rates between 4% and 40% have
been reported and can sometimes be reduced to 12% by
microwave thermosphere ablation.5 A review of local
treatment of breast cancer liver metastases found that
overall survival rates 3 years after RFA were between 43%
and 70%.4
Stereotactic body radiation therapy (SBRT) is generally
offered as an ablative and radical local treatment. In a phase
2 randomized trial, the addition of this directed therapy to
the standard-of-care palliative treatment appeared to lead to
longer overall survival.6 Long-term outcomes of another
phase 2 study also found longer overall survival in a group
of non-small cell lung cancer patients randomly assigned to
local consolidative therapy followed by standard mainte-
nance or observation (LCT arm) or to standard maintenance
therapy or observation (MT/O arm).7
Patients with liver metastases referred for SBRT are
ineligible for surgery and often are not the most suitablecandidates for thermal ablation.8 Many patients referred for
SBRT present with larger lesions than those considered
optimal for thermal ablation (3 cm) and with tumors for
which curative ablation with adequate margins (6 mm) is
not feasible.9,10 Several studies on SBRT for liver metas-
tases reported a 3-year local control of 66% to 91% and a 3-
year overall survival of 27% to 65%.11-13 Severe toxicity
(grade 3) was limited, and the treatment appeared to be
safe.14-17 Sporadically, grade 5 toxicity has been
described.12,18
Most series on SBRT for liver metastases included a
limited number of patients, with only 2 articles reporting
numbers that were well over 200.19,20 Both series investi-
gated factors associated with clinical outcomes after SBRT.
Mahadevan et al’s analysis was conducted between 2005
and 2017 within the international multi-institutional Radi-
osurgery Society Search (RSSearch) registry,20 and
Andratschke et al’s analysis was conducted between 1997
and 2015 within the database of the German Society of
Radiation Oncology (DEGRO).19 Both articles lacked
formal inclusion criteria, and information on toxicity was
not available from all centers in the RSSearch registry.
The present study aimed to validate the outcomes of
SBRT in a large, multi-institutional cohort of patients with
liver metastases recently treated according to a common
SBRT protocol. To the best of our knowledge, the outcomes




Since 2012, Dutch centers that use SBRT in the treatment
of liver tumors have collaborated on the development of
guidelines and on sharing clinical and technological expe-
rience. In 2013, they adopted a common SBRT protocol for
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istry that fulfilled the requirements of the General Data
Protection Regulations. The system was developed and
tested in close collaboration with the chief security officer
at Erasmus MC. A consortium agreement designed by the
Technology Transfer Office at xxx was signed by all
participating centers in the Netherlands and the center in
Belgium.
A description of the registry project and its aim was
submitted to the ethical committees of the participating
centers (xxx- MEC 2016-632) and was considered not to be
subject to the Medical Research Involving Human Subjects
Act. Patient, tumor and treatment characteristics were
recorded anonymously.
Planning and fractionation schemes
The clinical target volume was considered to be the same as
the gross target volume. No margin was applied to
compensate for microscopic tumor extension. By
consensus, we agreed on the following fractionation
schemes to encompass the periphery of the planning target
volume (PTV): 3  18 to 20 Gy, 5  11 to 12 Gy, 8  7.5
Gy, and 12  5 Gy. With the exception of the latter (12x5
Gy), all schemes correspond to a biological effective dose10
(BED10) > 100 Gy, being the BED10 of the 12-fraction
scheme 90 Gy. The PTV margins and prescription
isodose were left to the discretion of the centers.
The planning goal was to cover a high percentage of the
PTV (typically at least 95%) with the prescribed dose.
There were no limitations for the maximum PTV dose. In
principle, for each patient, the scheme with the lowest
possible number of fractions (highest BED10) not resulting
in organs at risk constraint violations was used for treat-
ment (Table EA1).21-23 However, when the metastasis was
close to the central biliary tract or near the large vessels,
several institutes preferred more protracted schemes, even
though no specific constraints had been defined for these
structures.
Endpoints
The frequency and method of follow-up were left to the
discretion of the centers and the referring specialists. Local
control was assessed per metastasis and by means of
computed tomography or magnetic resonance imaging; it
was defined as the absence of in-field progression (either
regrowth after initial decrease in size or reappearance of the
lesion after complete remission).18,19 In collaboration with
the radiologist, this information was collected from radi-
ology reports or by direct inspection of the images. For
liver metastases to be eligible for the local-control analysis,
a radiologic examination during follow-up was required.
Because of the configuration of the registry, only liver
metastases treated individually as independent targets
(PTVs) were considered for the local-control assessment.Overall survival was assessed in the Netherlands with
the support of the Dutch population register. If needed,
information was collected through general practitioners or
referral hospitals. The web-based registry did not provide
data for assessing any survival endpoints other than overall
survival.
Local control and survival time were both calculated on
the basis of the day that the last SBRT fraction had been
delivered. Toxicity was scored according to the Common
Terminology Criteria of Adverse Events (CTC-AE), v4.03.
Only events of grade 3 or greater were entered in the reg-
istry. Information on toxicity was obtained by consulting
hospital files and reports.
Patient eligibility
The treatment had to be delivered according to 1 of the 4
specified fractionation schemes, and at least 1 follow-up
time point had to be recorded.
Statistical analysis
The Kaplan Meier estimate was used to measure local
control and overall survival. The date of the last known
radiology examination was regarded as the last follow-up
date for local control. The influence of various prognostic
factors on local control and on toxicity (age, fractionation
scheme, liver segment, tumor diameter) was investigated
using univariate and multivariate (backward stepwise) Cox
regression analysis. An extra analysis was also carried out
on local control using the method proposed by Geskus24;
this considered death as a competing risk. The median
follow-up time was assessed using the reverse Kaplan
Meier method. The calculations were conducted using R
statistical software, version 2.13.0.
Results
Between January 1, 2013, and July 31, 2019, a total of 515
patients with 668 metastases were treated and entered into
the web-based registry. Patient, tumor, and treatment
characteristics are summarized in Table 1. The most
frequent primary tumors were colorectal, followed by lung
and breast tumors. Most patients were treated for 1 liver
metastasis. The treatment was usually delivered in segment
8, and the lowest number of treatments was delivered in
segment 3. The preferred fractionation scheme was 3  18
to 20 Gy, followed by 8  7.5 Gy, 5  11 to 12 Gy, and 12
 5 Gy.
Local control
In total, 447 individually treated metastases in 428 patients
(19 patients had 2 metastases) were included in the local-
control analysis. The median diameter was 27 mm (range, 8-
88 mm). The median follow-up time was 1.1 years (range,
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3  18-20 Gy 161 36.0
5  11-12 Gy 114 25.5
8  7.5 Gy 142 31.8
12  5 Gy 30 6.7
Abbreviation: ECOG Z Eastern Cooperative Oncology Group;
MWA Z microwave ablation;
RFA Z radiofrequency ablation; SBRT Z stereotactic body radiation
therapy.
* A total of 447 metastases were included in the local control
analysis.
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at 2 years, and 68% at 3 years (Fig. 1a). There was no sig-
nificant difference between groups regarding the primary
tumor (Fig. 1b) or the 4 fractionation schemes (Fig. 1c).
Univariate analysis showed no significant association of age,
tumor diameter, fractionation scheme, or location of the
metastases in the liver with local control. The combination of
factors also was not significant in multivariate analysis
(Table 2 and Table 3). When the 447 metastases were strat-
ified in 3 cohorts based on the length of follow-up (<6
months [n Z 131], 6 to <18 months [n Z 180], and 18
months [n Z 136]), we did not find significant associations
among the factors being studied. However, we found sig-
nificant differences between these 3 groups regarding frac-
tionation scheme (P Z .01), age (P Z .02), and tumor
diameter (P Z .03).
Application of the competing risk method showed
higher local-control rates than those obtained with the
classical approach: 88.4% versus 86.5% at 1 year, 80.3%
versus 74.9% at 2 years, and 76.7% versus 68.4% at 3 years
(Fig. 1d).
Overall survival
All 515 patients were included in the overall survival
analysis. The median follow-up time was 2.3 years (range,
0.1-5.9 years). Overall survival rates were 84% at 1 year,
63% at 2 years, and 44% at 3 years (Fig. 2).
Toxicity
Toxicity was grade 3 or greater in 20 of the 515 patients
(3.9%), grade 4 in 2 patients (0.4%), and grade 5 in 1 pa-
tient (0.2%). Table 4 presents an overview of the 23
observed toxicity events and grades. Most patients had 1
toxicity event,18 1 patient had 2 events, and 1 patient had 3
events.
The patient who developed grade 5 toxicity had been
treated with 3x20 Gy for 2 adjacent metastases (relapses
after RFA) situated in segments 1 and 4a. The central
biliary tract was located within the PTV including the 2
lesions and received a maximum dose of 69.6 Gy. Six
months after treatment, the patient developed biliary ste-
nosis. The disease also continued to progress. A biliary
stent was placed. The patient died 1 year after treatment.
The cause of death was evaluated as probably related to the
adverse event.
An episode of stomach perforation, grade 4, occurred
1.5 months after treatment in a patient with 2 metastases,
both located at the periphery of the liver in segment 2. Both
metastases were treated in 1 target. The radiation therapy
plan respected the stomach constraints, but high dose gra-
dients were delivered outside the liver in the direction of
the stomach. The patient underwent endoscopic surgery for
the stomach perforation.
Overall local control Overall local control









































5 x 11-20Gy (scheme 2)
8 x 7.5Gy (scheme 3)
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0
n at risk 447 202 91
n at risk 161 86 45 23 9
n at risk 355 168 78 33 15 3
18 6 2 2
40 11 3 1 1
34 17 8 5 2
2
114 49 21 7 3
142 57 21 9 4 1
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Fig. 1. (a) Overall local control. (b) Overall local control; metastases from different primary tumors. (c) Overall local
control; various fractionation schemes applied to treat liver metastases. (d) Overall local control; competing risk method.





ratio 95% CI P value
Hazard
ratio 95% CI P value
Scheme
1 (reference)
2 1.12 0.61-2.06 .71 1.65 0.62-4.42 .32
3 1.37 0.79-2.38 .26 0.55 0.15-2.10 .38
4 1.50 0.58-3.89 .41 0.79 0.10-6.36 .83
Age 0.99 0.97-1.01 .24 1.03 0.99-1.08 .18
Tumor diameter 1.00 0.98-1.02 .74 1.01 0.98-1.05 .49
Liver segment
1 (reference)
2 1.30 0.34-4.85 .70 0.97 0.16-5.82 .97
3 2.76 0.74-10.33 .13 - 0-infinity 1.00
4a 0.54 0.16-1.86 .33 0.17 0.02-1.59 .12
4b 1.52 0.46-4.98 .49 - 0-infinity 1.00
5 0.62 0.15-2.61 .52 0.89 0.18-4.43 .89
6 1.38 0.46-4.13 .56 0.25 0.03-2.37 .23
7 1.45 0.53-3.98 .47 0.13 0.01-1.27 .08
8 0.99 0.37-2.59 .97 0.34 0.08-1.43 .14

















n at risk 515 354 184 73 32 8
1 2 3 4 5
Fig. 2. Overall survival.




Hazard ratio 95% CI P value Hazard ratio 95% CI P value
Scheme
1 (reference)
2 1.17 0.63-2.19 .62 2.44 0.76-7.83 .13
3 1.59 0.87-2.91 .13 0.88 0.20-3.81 .87
4 1.34 0.49-3.65 .57 - 0-infinity 1.00
Age 0.99 0.97-1.01 .29 1.03 0.98-1.09 .21




2 1.32 0.35-4.94 .68
3 3.72 0.94-14.63 .06
4a 0.61 0.17-2.13 .44
4b 1.68 0.51-5.57 .39
5 0.72 0.17-3.02 .65
6 1.60 0.51-4.96 .42
7 1.70 0.59-4.90 .33
8 1.19 0.44-3.21 .74
Abbreviation: NA Z not assessed.
* The multivariate backward method showed that no factor remained in the model.
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in a patient with colorectal liver metastases who had been
treated with SBRT for a lesion in segment 1 that extended
to segments 5 and 8. One month before SBRT, microwave
ablation (MWA) had been delivered for a lesion in segment
4 (vicinity of the gallbladder). The PTV extended into the
most cranial and medial areas of the gallbladder, reaching a
maximum dose of 71.2 Gy and a 6-cc volume receiving
44 Gy. Nine months after treatment, perforation of the
gallbladder and a possible abscess were detected. Owing to
the very limited performance status related to disease pro-
gression, conservative treatment was recommended and
followed.
Regarding the incidence of severe toxicity, there was no
significant difference between the 4 fractionation schemes,
although toxicity was slightly higher in the treatments
delivered in a lower number of fractions. At 3 years, the
rate of severe toxicity was 9%, 22%, 3%, and 2% for the
fractionation schemes 3  18 to 20 Gy, 5  11 to 12 Gy, 8
 7.5 Gy, and 12  5 Gy, respectively. Univariate and
multivariate analyses showed that other factors such as age,
the tumor diameter, and the location of the metastasis in the
liver had no significant association with the development of
toxicity of grade 3 or greater (Table 2 and Table 3).
Discussion
This large, multi-institutional study confirmed that local
control is high and toxicity is limited after SBRT for liver
metastases. To our knowledge, no previously published
series has had a larger number of patients.Since the first publications in the 1990s, several cohort
studiesdand, more recently, some randomized trialsdhave
investigated the value to patients with limited metastatic
disease of integrating SBRT into the treatment frame-
work.6,7,25-32 Whereas the first studies showed that SBRT
controlled oligometastases effectively and that patients
could be treated safely at multiple body sites, the more
recent randomized trials showed that local directed or
consolidative therapy including SBRT was associated with
improved survival.
Most reports on SBRT for liver metastases have
been published in cohorts of <100 patients; a minority
have reported on 100 to 200 patients, and to our
knowledge, only 2 series have reported on well over 200
Table 4 Toxicity Description (Grade and Type of Event)










3 Abdominal pain Colorectal 1 5 27
3 Abdominal pain Colorectal 1 2 22
3 Bile duct stenosis Colorectal 1 8 8
3 Bile duct stenosis Stomach 2 8,4a Multiple*
3 Bile duct stenosis Colorectal 2 8 29
3 Chest wall pain Colorectal 2 6 40
3 Chest wall pain Breast 4 4a,4b Multiple*
3 Cholecystitis Colorectal 2 8 40
3 Cholecystitis Colorectal 2 4a,4b Multiple*
3 Fatigue Lung 1 7 35
3 Fatigue Colorectal 2 1 35
3 Fibrosis deep connective
tissue
Colorectal 2 8 34
3 Flank pain Other 2 5 41
3 Fracture Colorectal 1 1 14
4 Gallbladder perforation Colorectal 3 1 41
4 Gastric perforation Lung 4 2,2 Multiple*
3 Hematoma Colorectal 3 4a 14
5 Hepatobiliary disorders Colorectal 1 1,4a Multiple*
3 Nausea Lung 2 8 59
3 Nausea Colorectal 3 5 20
3 Pneumothorax Lung 2 8 59
3 Portal vein thrombosis Colorectal 1 8 8
3 Vomiting Lung 2 8 59
Abbreviation: CTC-AE Z common terminology criteria of adverse events.
* Multiple metastases treated in one target volume.
















Lee et al, 200635 Phase I Mixed 70/143* Median 41.8 Gy in 6
fractions
71-NRP 60-30
Andratschke et al, 201533 Retrospective Mixed 74/91 3-5  5-12.5 Gy 74.7-48.3 77-30
Goodman et al, 201612 Retrospective Mixed 81/106 Median 54 Gy in 3-5
fractions
96-91 89.9-44
Joo et al, 201734 Retrospective Colorectal 70/103 45-60 Gy in 3-4 fractions 93-68 2y 75
Dawson et al, 201914 Phase I Mixed 23/NRP 10  3.5-5 Gy NRP NRP
Clerici et al, 202011 Retrospective Mixed 202/268 3  25 Gy 92-84 79-27
Mahadevan et al, 201820 Retrospective Mixed 427/568y Median 45 Gy in 1-5
fractions
80-63 70-30
Andratschke et al, 201819 Retrospective Mixed 474/623z 1-13  3-37.5 Gy
Median 18.5 Gy
76.1-55.7 70-29
Present study, 2020 Prospective Mixed 515/668x 3  18-20 Gy
5  11-12 Gy
8  7.5 Gy
12  5 Gy
87-68 84-44
Abbreviations: NRP Z not reported; SBRT Z stereotactic body radiation therapy.
* Two patients from the 70 were removed from the study.
y A total of 430 metastases were evaluable for local control.
z A total of 607 metastases were evaluable for local control.
x A total of 447 metastases were evaluable for local control.
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a selection of these studies are presented in Table 5. For the
selection of articles, priority was given to recent publica-
tions and to those including a large number of patients. Our
local-control results at 1 year (87%) and 3 years (68%) are
within the range of values of the series that had a more
limited number of patients, with 1-year local control of
71% to 96% and 3-year local control of 48% to 91%. Our
results compared particularly well with those from the
registries at 1 year (76%-80%) and 3 years (56%-63%).
Taking into account only the series treating patients with
more hypofractionated schemes, our results seemed to be
inferior at long term (2-3 years).11,12 Although a BED10 >
100 Gy has been associated with a higher chance of local
control than a BED10  100 Gy, we were not able to detect
a significant difference in local control according to this
parameter.20,34,37 Whereas 3 of the fractionation schemes in
our series had a BED10 > 100 Gy, 1 did not, and although
the number of patients treated with 12 fractions was not
large, this effect may have influenced the outcomes. Our
results may also have been influenced by the fact that
roughly one-third of our population was treated with a
BED10 of 108 Gy. Ohri et al showed that after a BED10
close to but >100 Gy, the probability of tumor control may
be lower than for a BED10 of 150 Gy or even 200 Gy.37
Such high doses may be more effective for tumor control
but cannot be safely delivered to metastases located in the
vicinity of the luminal gastrointestinal structures and
probably not to metastases adjacent to the central biliary
tract. No direct comparison can be done with other series
regarding the location of the metastases in the liver and the
possible influence of this factor in our local-control results.
Only Meyer et al, in a phase 1 trial, limited the inclusion of
patients to those with metastases located outside of the
central liver zone.15 Local control was 100% at a median
follow-up of 2.5 years in 14 patients treated with 1 fraction
of 35 or 40 Gy.
Besides dose, tumor histology has been reported as a
factor that influenced local control.19 In the DEGRO reg-
istry, metastases from colorectal cancer had significantly
worse control at 1 year (67%) compared with breast cancer
(91%). In our series, no significant difference in local
control between primaries was found. A possible explana-
tion may be that the percentage of metastases from non-
colorectal cancer was very low (19.8%) compared with the
German series (51.9%). Breast cancer as the primary tumor
was observed in 4% of our patients, whereas in the DEGRO
registry, this percentage reached 13.3%.
Although tumor diameter in our series was not signifi-
cantly related to local control, some publications showed
significantly lower local control with metastases of >3 cm
or a volume of >40 cc or 75.2 cc.17,20,35 Although some
studies limited the tumor diameter to a cumulative sum of
 6 cm, we and others added no restrictions regarding
size.11,12,19,20,34,35
Overall survival rates in our series at 1 and 3 years (84%
and 44%, respectively) compared well with other seriesincluding the 2 registries (Table 5). Differences in overall
survival might be influenced by variation in inclusion
criteria regarding the extent and severity of the extrahepatic
disease accepted in the different studies.38
In many series, the reported rates of toxicity of grade
3 or greater have been low, with ranges between 0% and
5%, and fewer authors have reported between 10% to
15%.11-14,17,19,20,33-36 With a 3.9% rate of toxicity of grade
3 or greater, our series compared well with the findings in
the literature.
One episode of grade 5 hepatobiliary toxicity and 3 of
grade 3 biliary stenosis were observed in our series.
Goodman et al reported hepatic toxicity of grade 3 or
greater in 4 patients (4.9%), of grade 3 in 1 patient, and of
grade 4 in 2 patients, as well as 1 hepatotoxicity-related
death.12 Total dose was associated with hepatic toxicity of
grade 3 or greater. Hoyer et al reported an isolated case of
liver failure after treating a patient with 3 fractions of 10
Gy.18 It is uncertain whether this fatal incident was related
to irradiation or to thrombosis. Particular attention should
be devoted to toxicity related to the central biliary tree.
After single-fraction SBRT in a group of 14 patients, Meyer
et al reported 4 biliary stenoses adjacent to the treated
tumor.15 Osmudson and collaborators proposed a surrogate
structure for the central biliary tract defined by a 15-mm
expansion of the portal vein from the splenic confluence
to the first bifurcation of the left and right portal veins.39
The treatments for primary and metastatic liver tumors
were delivered in 1 to 5 fractions. Based on the surrogate
structure, dosimetric factors predictive of hepatobiliary
toxicity of grade 3 or greater were identified (in 3 fractions:
VBED1033.8 < 21 cc; VBED1032 < 24 cc). There were 2
instances of grade 5 toxicities, 1 in a patient treated for
cholangiocarcinoma and 1 in a patient treated for colorectal
liver metastasis. Finally, investigators in the NRG-GI001
trial proposed a dose-volume objective to limit the high-
dose regions in the central biliary tree to treat patients
with cholangiocarcinoma. Although not specifically
developed for patients with liver metastases, this objective
(0.5 cc  70 Gy in 15 fractions) may be considered when
treating these patients with SBRT. Delivering the treatment
in a larger number of fractions may also help to overcome
this toxicity, as suggested by Dawson et al.14
Gastrointestinal toxicity of grade 4 was found in 1 pa-
tient with perforation of the stomach. This effect was most
probably dose related. Lee et al reported gastrointestinal
toxicity of grade 3 or greater, including gastritis and
nausea.35 Two patients (2.9%) developed late toxicity of
grade 3 or greater: 1 developed grade 4 and 1 developed
grade 5. In both patients, toxicity was related to the small
bowel (bleed and obstruction). Andratschke et al also re-
ported acute gastric toxicity with ulcer bleeding in 1 patient
(<1%).19
Chest wall pain and fibrous deep connective tissue,
grade 3, were observed in 3 patients in our series. In those
patients, the liver metastasis was located close to the
thoracic/abdominal wall. Dunlap et al studied chest wall
Volume -  Number -  2020 Dutch-Belgian registry for liver metastases 9toxicity involving pain and/or rib fracture after SBRT.40
When possible, the risk of adverse events can be reduced
by limiting the dose to the chest wall volume.
Patients who are referred for SBRT are typically not
candidates for surgery, RFA, or MWA. Unfortunately, ran-
domized phase 3 trials comparing SBRTwith other ablative
treatment strategies are lacking. Moreover, as SBRT pa-
tients are frequently heavily pretreated, direct comparison
between different ablative treatments is difficult. Three
retrospective single-institution studies compared SBRT
with RFA or MWA for liver metastases.41-43 Freedom from
local progression appeared to favor SBRT to RFA for tu-
mors 2 cm or to MWA for tumors >3 cm. However, it is
difficult to draw firm conclusions from these results.
Our registration study has a few drawbacks. Part of the
data were retrospectively registered, as it took some time to
build up the online registration tool, and although we
agreed on the different fractionation schedules beforehand,
dose prescription was left at the discretion of the individual
centers, potentially influencing the results. However, this
registry reports on the largest number of patients treated
with SBRT for liver metastases in daily clinical practice.
In conclusion, this multi-institutional study of liver
metastases treated with SBRT in a large patient cohort
confirms earlier findings of high rates of local control and
limited toxicity. Our achievement highlights the importance
of including SBRT in multidisciplinary approaches to liver
metastases.References
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